A.P. Meert (Brussels, Belgium), K. Zarogoulidis (Thessaloniki, Greece)
Muldisciplinary conference (MDC), oncological program (OP) and practice guidelines (GL): The experience of the lung cancer (LC) clinic of a cancer hospital
J. P. Sculier, L. Nathalie, A. P. Meert, I. C. S. Toth, M. Paesmans, T. Berghmans (Brussels, Belgium)
|    |
Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT)
A. Tufman, T. Schuster, A. Borgmeier, M. Schmidt, K. Ulm, M. Flentje, R. M. Huber (Munich, Würzburg, Germany)
| |
Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT
M. Kreuter, J. Vansteenkiste, J. R. Fischer, W. Eberhardt, H. Zabeck, J. Kollmeier, M. Serke, N. Frickhofen, M. Reck, W. Engel-Riedel, S. Neumann, M. Thomeer, C. Schumann, P. De Leyn, T. Graeter, G. Stamatis, F. Griesinger, M. Thomas (Heidelberg, Loewenstein, Essen, Berlin, Hemer, Wiesbaden, Großhansdorf, Cologne, Göttingen, Ulm, Oldenburg, Germany; Leuven, Genk, Belgium)
| |
Exhaled breath temperature in NSCLC: Could be a new non invasive marker?
G. E. Carpagnano, G. Scioscia, D. Lacedonia, A. Spanevello, D. Martinelli, V. Saliani, C. Ruggieri, M.P. Foschino-Barbaro (Foggia, Italy)
| |
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut)
M. Sebastian, J. Chih-Hsin Yang, L. Sequist, M. Schuler, T. Mok, N. Yamamoto, K. O'Byrne, V. Hirsh, S. Geater, C. Zhou, D. Massey, V. Zazulina, Y. L. Wu (Frankfurt, Essen, Germany; Taipei, Taiwan; Boston, United States Of America; Hong Kong, Shanghai, Guangzhou, China; Wakayama, Japan; Dublin, Ireland; Montreal, Canada; Songkla, Thailand; Bracknell, United Kingdom)
| |
The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib
D. I. Park, S. Y. Kim, J. O. Kim, S. S. Jung, H. S. Park, J. Y. Moon, C. U. Chung, J. E. Lee (Daejeon, Republic Of Korea)
| |
Is there a change in pulmonary function in patients with COPD and primary lung cancer treated with radiofrequency ablation (RFA)?
E. Skondras, J. Beeson, S. Kaul, P. Dalal (London, United Kingdom)
| |
Treatment of pulmonary carcinoid: Are there new options?
D. Yabar, S. Padrones, R. Pascual, S. Aso, R. López-Lisbona, F. Rivas, J. Dorca (Barcelona, Spain)
| |